Kathy Robinson, PhD

Kathy Robinson, PhD

Associate Professor
Center for Clinical Research

    About me

    Kathy Robinson has been involved with medical research for more than 20 years. Throughout that time, she has collaborated with many excellent clinicians and discovery science researchers to secure grants and move new cardiovascular and cancer treatments forward. 

    She enjoys meeting patients and is grateful for all of those who enroll in a clinical trial. Through these trials the research department learns so much from those who are willing to enroll. These clinical trials can lead to newly developed treatments. Robinson finds each patient is unique and brings a fresh perspective to studies. She looks forward to a continued collaboration with the faculty of SIU School of Medicine.

    Gender

    Female

    Education & training

    Doctorate Degree
    Southern Illinois University, Carbondale, IL
    Undergraduate Degree
    BS, Eastern Illinois University, Charleston, IL
    Fellowship
    Research Fellowship, Prairie Education and Research Cooperative, Springfield, IL

    Clinical trials

    Trial
    Simmons Cancer Institute

    A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Active recruiting

    The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative,

    Active recruiting

    The purpose of this study is to evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy.

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk

    Active recruiting

    The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

    Active recruiting

    The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice.

    Contact: Kathy Robinson 217-545-1946